Researchers discover how SARS-CoV-2 infects and replicates in host cells
A team has revealed how SARS-CoV-2 infects cells, suggesting that targeting its RNA with drugs would stop the virus replicating.
List view / Grid view
A team has revealed how SARS-CoV-2 infects cells, suggesting that targeting its RNA with drugs would stop the virus replicating.
Anti-inflammatory therapies for inflammatory bowel disease could aid recovery from COVID-19 as they target an enzyme involved in both diseases.
A new analysis reveals that the course of SARS-CoV-2 infection and the immune response it provokes is completely different in adults and children.
According to a new study, the SARS-CoV-2 virus is accumulating genetic mutations, including one called D614G which may have made it more contagious.
Researchers have found that aprotinin, an approved drug for influenza in Russia, combats SARS-CoV-2 in cells.
Researchers have found the genome of COVID-19 and infected cell syncytia in the respiratory cells of deceased patients, potentially explaining long-term coronavirus effects.
According to a new study, blood clots in patients with severe COVID-19 are caused by an autoimmune antibody that circulates in the blood and attacks cells.
Binding of SARS-CoV-2 spike proteins to the brain’s endothelial cells can cause the blood-brain barrier to become leaky, potentially causing the neurological symptoms associated with COVID-19.
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.
Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
Researchers used flow cytometry to characterise which types of T cells are involved in the immune response to COVID-19 and what they target.
Using cryo-electron microscopy and site-specific mass spectrometry, researchers have mapped the glycans that shield HIV from the immune system.
A new report has said that by 2023, the flow cytometry market will be worth $8.88 billion, partly due to an increase in stem cell research.
Using lung organoids, researchers have shown that 48 hours after SARS-CoV-2 infection, the innate immune response began.
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.